NRC-2694

NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR) . It has anti-cancer and anti-proliferative properties. (In Vitro) :NRC-2694 (80 ng) induce comparable inhibition of EGFR expression. (In Vivo) :NRC-2694 (10 mg/kg) regresses the tumor in mice. The maximum tolerated dose of NRC-2694 in male and female mice is 2000 mg/kg (p.o.), in toxicity studies .